Regulators will look into whether mergers cause higher drug prices, lower innovation or anticompetitive conduct
An international team of regulators from the EU, Canada, UK and United States has formed a working group to evaluate mergers in the pharmaceutical industry, and whether they have negative effects.
The initiative, announced on 16 March, is a joint effort from authorities including the European Commission’s competition department, the Canadian Competition Bureau, the UK’s Competition and Markets Authority and the US Department of Justice.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.